Cargando…
Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer
OBJECTIVE: We evaluated the usefulness of human epididymis protein 4 (HE4), a tumor marker, during and after treatment in patients with ovarian cancer (OC). METHODS: We included Japanese patients newly diagnosed with OC treated at the National Cancer Center Hospital between 2014 and 2021. The HE4 le...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Obstetrics and Gynecology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375218/ https://www.ncbi.nlm.nih.gov/pubmed/37380167 http://dx.doi.org/10.5468/ogs.23024 |
_version_ | 1785078990801731584 |
---|---|
author | Uno, Masaya Matsuo, Rie Maezawa, Naoki Kato, Tomoyasu |
author_facet | Uno, Masaya Matsuo, Rie Maezawa, Naoki Kato, Tomoyasu |
author_sort | Uno, Masaya |
collection | PubMed |
description | OBJECTIVE: We evaluated the usefulness of human epididymis protein 4 (HE4), a tumor marker, during and after treatment in patients with ovarian cancer (OC). METHODS: We included Japanese patients newly diagnosed with OC treated at the National Cancer Center Hospital between 2014 and 2021. The HE4 levels were measured in the serum stored during diagnosis. To evaluate the concordance between HE4 and the imaging results, we employed sequential pairs of blood sampling points and the results of imaging examinations. We compared the timing of the elevated HE4 levels, imaging diagnoses, and elevated cancer antigen 125 (CA125) levels in patients with recurrence. The Ethics Review Committee of our institution (2021-056) reviewed this study. RESULTS: Forty-eight patients with epithelial OC were eligible for enrollment. The sensitivity, specificity, and positive and negative predictive values of HE4 (criterion, 70 pmol/L) for disease progression during the follow-up period were 79.4%, 59.1%, 32.5%, and 92.0%, respectively (time point, n=317). We evaluated the relationship between HE4 and CA125 variability and disease status (recurrence or no recurrence). For recurrence, the sensitivity and negative predictive value of HE4 (criterion, 70 pmol/L), CA125 (criterion, 35 U/mL), and combination of HE4 and CA125 were 77.8%, 85.2%, and 92.6% and 75.0%, 82.6%, and 88.9%, respectively (n=48). Among the 27 patients who exhibited recurrence, 16 and nine showed earlier increased HE4 levels than the relevant imaging and CA125 levels, respectively. CONCLUSION: HE4 may be a valuable marker for follow-up during and after OC therapy. A complementary role for HE4 and CA125 measurements was suggested for follow-up observations. |
format | Online Article Text |
id | pubmed-10375218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Society of Obstetrics and Gynecology |
record_format | MEDLINE/PubMed |
spelling | pubmed-103752182023-07-29 Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer Uno, Masaya Matsuo, Rie Maezawa, Naoki Kato, Tomoyasu Obstet Gynecol Sci Original Article OBJECTIVE: We evaluated the usefulness of human epididymis protein 4 (HE4), a tumor marker, during and after treatment in patients with ovarian cancer (OC). METHODS: We included Japanese patients newly diagnosed with OC treated at the National Cancer Center Hospital between 2014 and 2021. The HE4 levels were measured in the serum stored during diagnosis. To evaluate the concordance between HE4 and the imaging results, we employed sequential pairs of blood sampling points and the results of imaging examinations. We compared the timing of the elevated HE4 levels, imaging diagnoses, and elevated cancer antigen 125 (CA125) levels in patients with recurrence. The Ethics Review Committee of our institution (2021-056) reviewed this study. RESULTS: Forty-eight patients with epithelial OC were eligible for enrollment. The sensitivity, specificity, and positive and negative predictive values of HE4 (criterion, 70 pmol/L) for disease progression during the follow-up period were 79.4%, 59.1%, 32.5%, and 92.0%, respectively (time point, n=317). We evaluated the relationship between HE4 and CA125 variability and disease status (recurrence or no recurrence). For recurrence, the sensitivity and negative predictive value of HE4 (criterion, 70 pmol/L), CA125 (criterion, 35 U/mL), and combination of HE4 and CA125 were 77.8%, 85.2%, and 92.6% and 75.0%, 82.6%, and 88.9%, respectively (n=48). Among the 27 patients who exhibited recurrence, 16 and nine showed earlier increased HE4 levels than the relevant imaging and CA125 levels, respectively. CONCLUSION: HE4 may be a valuable marker for follow-up during and after OC therapy. A complementary role for HE4 and CA125 measurements was suggested for follow-up observations. Korean Society of Obstetrics and Gynecology 2023-07 2023-07-15 /pmc/articles/PMC10375218/ /pubmed/37380167 http://dx.doi.org/10.5468/ogs.23024 Text en Copyright © 2023 Korean Society of Obstetrics and Gynecology https://creativecommons.org/licenses/by-nc/3.0/Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Uno, Masaya Matsuo, Rie Maezawa, Naoki Kato, Tomoyasu Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title | Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title_full | Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title_fullStr | Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title_full_unstemmed | Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title_short | Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
title_sort | evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375218/ https://www.ncbi.nlm.nih.gov/pubmed/37380167 http://dx.doi.org/10.5468/ogs.23024 |
work_keys_str_mv | AT unomasaya evaluationoffollowupobservationusinghumanepididymisprotein4atumormarkerinpatientswithovariancancer AT matsuorie evaluationoffollowupobservationusinghumanepididymisprotein4atumormarkerinpatientswithovariancancer AT maezawanaoki evaluationoffollowupobservationusinghumanepididymisprotein4atumormarkerinpatientswithovariancancer AT katotomoyasu evaluationoffollowupobservationusinghumanepididymisprotein4atumormarkerinpatientswithovariancancer |